First human test of new Tumor-Injected therapy for tough cancers
NCT ID NCT06171750
Summary
This is an early-stage safety study for a new drug called ANK-101, which is injected directly into tumors. It aims to find a safe dose for people with advanced solid cancers that have stopped responding to standard treatments. The study will test the drug alone in different types of tumors and also test it combined with another cancer drug for a specific skin cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Cancer Institute
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 2M9, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Providence Cancer Institute
RECRUITINGPortland, Oregon, 97213, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.